VYTORIN
Total Payments
$59,765
Transactions
7
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $51,255 | 1 | 0 |
| 2017 | $8,510 | 6 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $59,701 | 2 | 99.9% |
| Food and Beverage | $63.51 | 5 | 0.1% |
Payments by Type
Research
$59,701
2 transactions
General
$63.51
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ISCHEMIA International Study of Comparative Health Effectiveness with Medical and Invasive Approaches | Merck Sharp & Dohme Corporation | $59,701 | 0 |
Top Doctors Receiving Payments for VYTORIN
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $59,765
Product Information
- Type Drug
- Total Payments $59,765
- Total Doctors 5
- Transactions 7
About VYTORIN
VYTORIN is a drug associated with $59,765 in payments to 5 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $51,255 was paid across 1 transactions to 0 doctors.
The most common payment nature for VYTORIN is "Unspecified" ($59,701, 99.9% of total).
VYTORIN is associated with 1 research study, including "ISCHEMIA International Study of Comparative Health Effectiveness with Medical and Invasive Approaches" ($59,701).